Finanzen von Kyntra Bio Inc (KYNB)KYNBKyntra Bio Inc

Evaluating the bottom line, Kyntra Bio, Inc. maintains a gross margin of -81.45%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1385.11%, while the net margin is -139.49%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively KYNB converts its operational activities into shareholder value.

In the context of the broader market, KYNB competes directly with industry leaders such as PPBT and ATNM. With a market capitalization of $28.55M, it holds a significant position in the sector. When comparing efficiency, KYNB's gross margin of -81.45% stands against PPBT's N/A and ATNM's 100.00%. Such benchmarking helps identify whether Kyntra Bio, Inc. is trading at a premium or discount relative to its financial performance.

Kyntra Bio has shown a significant improvement in financial performance, with total revenue of $3.7 million in Q1 2026, up from $2.7 million in Q1 2025, and a net income of $12 million in Q2 2026, indicating a potential for sustainable growth.